Search:

Login | Subscribe

Home > Companies > Proximagen Neuroscience

Price	Market	Sector	Market Cap
145.00p (0.00p) 0.00%	AIM	Medicine and Biotech Research	£31.29m

Add to company folder | Print

Related Companies

AGY	10.00p	0.00%
APH	4.62p	0.00%
AZH	p
BBI	p
CEN	p
CBF	2.00p	0.00%
COT	91.50p	-0.54%
CRX	2.62p	0.00%
CYX	p
LAC	p
EVC	25.75p	0.00%
FUL	3.12p	0.00%
FUM	27.25p	-0.91%
GMX	1.75p	0.00%
GNI	p
GWP	29.50p	-0.84%
HML	0.42p	0.00%
MLR	p
MMG	7.25p	0.00%
MPM	9.75p	5.41%

Commentary

Specialty drug discovery and development company focused on neuro degenerative diseases

Recent Articles

Proximagen Neuroscience	16/10/2008
Proximagen	18/08/2008
Proximagen bullish after interim loss	29/08/2007
Newcomer - Proximagen Neuroscience	10/05/2005

Recent Announcements

DIRECTORS' SHARE PURCHASE	03/12/2008
Major Interest in Shares	28/11/2008
Issue of Equity	27/10/2008
Grant of Options	17/10/2008
Milestone and equity investment	14/10/2008
Shareholding	01/09/2008
Interim Results	13/08/2008
Notice of Results	07/08/2008
Shareholding	25/07/2008
$232 Million Licensing Agreem	14/07/2008
More

Articles from the Sector

Stroke hope at ReNeuron	28/11/2008
Futura Medical	28/11/2008
Option deal boosts ImmuPharma	25/11/2008
Digital imager targets AIM	24/11/2008
Vectura loses interim £11.7m	24/11/2008
GW trims loss	19/11/2008
Asterand	18/11/2008
EU trial cheers Plethora	07/11/2008
IS Pharma	05/11/2008
Animalcare nurturing high-margin growth	03/11/2008
More

Financial History

Financial Year End	30/11/2004	30/11/2005	30/11/2006	30/11/2007
Currency	GBP	GBP	GBP	GBP
Turnover	0.58	0.88	0.74	0.28
Operating Profit	0.01	-0.49	-2.25	-3.48
Pretax Profit	0.02	-0.08	-1.69	-2.93
Earnings After Tax	0.01	0.00	-1.66	-2.97
Profit Available For Dividend	0.00	0.00	0.00	0.00
Ordinary Dividends	0.00	0.00	0.00	0.00
Retained Profit	0.00	0.00	-1.66	-2.97
Shareholders Funds	0.41	13.18	11.57	8.67
Net Current Assets	0.41	13.09	11.34	8.32
Adjusted Earnings Per Share Undiluted	0.12	0.03	-8.30	-14.80
Adj Earnings Per Share	0.12	0.03	-8.30	-14.80
Dividend Per Share	0.00	0.00	0.00	0.00

Chart

Click here for interactive charting

Company Details
Address	Hodgkin Building, Guy's Campus, King's College London, London, SE1 1UL
Telephone	020 7848 6938
Fax	020 7848 6034
Executives
Chairman	Bruce Campbell (0.30% holding)
Chief Executive	Kenneth Mulvany (3.90% holding)
Finance Director	James Hunter (0.00% holding)
Chief Scientific Officer	Peter Jenner (8.90% holding)
Main Shareholders
	IP2IPO Management II: 19.8% Lansdowne Partners: 7.6% Gartmore: 5.4% Invesco: 5.1%
Advisers
Nominated Adviser	Canaccord Adams
Nominated Broker	Canaccord Adams
Solicitors	Fasken Martineau
Auditors	Baker Tilly
Registrar	Capita Registrars

Commentary
Specialty drug discovery and development company focused on neuro degenerative diseases
Company Data
Code	PRX
Sedol	GB00B06FMX
Shares In Issue	21.582 m
Indices
Entry on AIM	31/03/2005
Interim Results	Aug
Final Results	Apr
Year End	Nov
Accounts Due	May
Int div payment	n/a
Fin div payment	n/a
Int net div per share	nil
Fin net div per share	nil
Probable CGT relief	Yes